61825-94-3
61825-94-3
Chemical Structure
Oxaliplatin
- CAS No.: 61825-94-3
- Formula:C8H14N2O4Pt
- Molecular Weight:397.29
InChIKey: ZROHGHOFXNOHSO-BNTLRKBRSA-L
SMILES: O=C(O1)C(O[Pt]21[NH2][C@@H]3CCCC[C@H]3[NH2]2)=O
Biological Activity: Oxaliplatin is a DNA synthesis inhibitor. Oxaliplatin causes DNA crosslinking damage, prevents DNA replication and transcription and induces apoptosis. Oxaliplatin can be used for cancer research[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Oxaliplatin | 99.65% | Oxaliplatin is a DNA synthesis inhibitor. Oxaliplatin causes DNA crosslinking damage, prevents DNA replication and transcription and induces apoptosis. Oxaliplatin can be used for cancer research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Oxaliplatin (Standard) | 99.99% | Oxaliplatin (Standard) is the analytical standard of Oxaliplatin. This product is intended for research and analytical applications. Oxaliplatin is a DNA synthesis inhibitor. Oxaliplatin causes DNA crosslinking damage, prevents DNA replication and transcription and induces apoptosis. Oxaliplatin can be used for cancer research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Oxaliplatin-d10 | Oxaliplatin-d10 is a deuterium labeled Oxaliplatin (HY-17371). Oxaliplatin is a DNA synthesis inhibitor. Oxaliplatin causes DNA crosslinking damage, prevents DNA replication and transcription and induces apoptosis. Oxaliplatin can be used for cancer research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Raymond E, et al. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol. 1998 Oct;9(10):1053-71. [Content Brief]
- [2]. Mohammed MQ, et al. Oxaliplatin is active in vitro against human melanoma cell lines: comparison with NSC 119875 and NSC 241240. Anticancer Drugs. 2000 Nov;11(10):859-63. [Content Brief]
- [3]. Pendyala L, et al. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res. 1993 Dec 15;53(24):5970-6. [Content Brief]
